Financial news, mergers and acquisitions, partnerships, and alliances.
Qiagen's revenues grew 6 percent at constant exchange rates to $349.0 million, besting the average Wall Street estimate of $346.6 million.
The firm's life science segment grew revenues 8 percent, but revenues from its diagnostics segment saw revenues retreated 4 percent.
The firm said that immunoassays had 19 years in a row of double-digit growth, driven in part by an automated workflow approach to achieving lab efficiencies.
Interpace Diagnostics said that the test will now be covered for Cigna's roughly 15 million members nationwide.
The company is collaborating with hospitals to implement sequencing and machine learning approaches to pinpoint the molecular etiology of autism earlier in age.
